Circumferential pulmonary-vein ablation for chronic atrial fibrillation.

By H. Oral, C. Pappone, A. Chugh, Eric D. Good, F. Bogun, F. Pelosi, E. Bates, M. Lehmann, G. Vicedomini, G. Augello and 4 more. New England Journal of Medicine, 2006

972 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/5b0961e5e31caf66ee0c527c17cea7f77c3a67bc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. M. Ezekowitz
2. Rick A. Nishimura
3. Stanley Nattel
4. Gerhard Hindricks

Citations in the corpus

• 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation (2017, background): “Table 7 shows the outcomes of four trials of catheter ablation for persistent AF.(245,733,1026,1030) Despite the widespread performance of AF ablation on patients with persistent AF, no ablation catheters have received FDA or CE Mark labeling specifically for the indication of ablation of persistent”
• ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Commit (2006, positive): “Catheter ablation should be considered to maintain sinus rhythm in selected patients who failed to respond to antiarrhythmic drug therapy.(134) In patients with AF, the ventricular rate may accelerate excessively during exercise even when it is well-controlled at rest.”
• 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. (2014, neutral): “AF catheter ablation is reasonable for selected patients with symptomatic persistent AF refractory or intolerant to at least 1 class I or III antiarrhythmic medication (157, 161-163).”